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Abstract
In England, the National Institute for Health and Care Excellence guideline for familial breast cancer recommends chemopre-
vention for women at high and moderate familial risk of breast cancer. However, prescribing of chemoprevention has not
improved since the introduction of the guideline in 2013. The study aims to identify the current practice, in England, of familial
cancer specialists offering chemoprevention and recommending prescribing in primary care. This was an anonymized national
cross-sectional survey of familial breast cancer risk services in England. Lead clinicians were sent an online survey link. The
survey questions included whether chemoprevention was offered/considered for high- and moderate-risk women, when chemo-
prevention prescribing and recommendation to primary care started, medications prescribed, age groups considered for chemo-
prevention, and existence of a shared prescribing protocol with primary care. The survey was sent to 115 hospital services;
responses from 50 services (43%) were included in the analysis. Of the 40 services offering chemoprevention for high-risk
women, 15 (38%) did not prescribe but 31 (78%) recommended prescribing to primary care. Of the 31 services considering
chemoprevention for moderate risk, eight (26%) did not prescribe with 26 (84%) recommended prescribing to primary care. Only
three services reported having a shared protocol with primary care.Within 3 years of the guidelines, many services recognized the
role of chemoprevention for both high andmoderate risk with a key role for primary care to initiate prescribing. However, there is
still room for improvement.
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Introduction
Breast cancer is the most common cancer in women world-
wide (World Cancer Research Fund 2019). In developed
countries, one in eight women will develop breast cancer in
their lifetime (Cancer Research UK 2018). Around 5–10% of
breast cancers are caused by an inherited faulty gene such as
the BRCA1 and BRCA2 genes (Cancer Research UK 2018).
Family history of breast and related cancers is recognized as a
risk factor and has been used to stratify disease risk (Cancer
Research UK 2018; NICE 2013b). For instance, in England,
the National Institute for Health and Care Excellence (NICE)
categorizes familial breast cancer (FBC) risk into near popu-
lation risk (lifetime risk < 17% from age 20 and < 3% between
ages 40 and 50), moderate risk (lifetime risk of 17–29% from
age 20 or 3–8% between ages 40 and 50), and high risk (life-
time risk of ≥ 30% from age 20 or > 8% risk between ages 40
and 50) (NICE 2013b).
At present, FBC is not routinely screened for and women
are assessed opportunistically when they present with con-
cerns about their family history (NICE 2013b; Qureshi et al.
2020).Women identified at risk of FBC are usually referred to
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specialist for further assessment and management of their
breast cancer risk. The pathway to specialist care is based on
the local protocol. Most commonly all women are referred to
specialist family history clinics, with moderate risk assessed
and followed up in this setting, while those confirmed to be at
high risk referred to clinical genetics for more detailed
counseling (NICE 2013b; Smith et al. 2016b). The options
for risk reduction measures include increased surveillance,
prophylactic surgery, and chemoprevention (NICE 2013b).
Chemoprevention can reduce the incidence of breast cancer
by over 30% (Cuzick et al. 2013).
In 2013, the English NICE guideline for FBC recommend-
ed that women at high risk of FBC be offered chemopreven-
tion (tamoxifen or raloxifene). In 2017, the guideline was
updated to include anastrozole as chemoprevention for post-
menopausal women. For women at moderate risk of FBC,
chemoprevention should be considered (NICE 2013b). This
difference in terminology reflects the strength of the recom-
mendation: the word offer is used to reflect a strong recom-
mendation, usually where there is clear evidence of benefit,
while the word consider is used to reflect a recommendation
for which the evidence of benefit is less certain (NICE 2014).
Chemoprevention medications are usually initiated by spe-
cialists and primary care may later take over prescribing of
chemoprevention for the recommended 5-year course. An ob-
servational study using national primary care prescribing data
has shown a slow uptake of this updated NICE guideline;
assuming 10% of all eligible women would accept the offer
of chemoprevention, the study estimated an 83% shortfall
against the predicted 50,000 uptake (Curtis et al. 2018).
Anecdotally, this may be due to specialists not
recommending treatment to women with moderate risk.
Qualitative research found that general practitioners are more
willing to continue prescribing chemoprevention if it was ini-
tiated in secondary care under a shared care agreement
(Rainey et al. 2020; Smith et al. 2017). A further consideration
is the current practice of specialist recommending chemopre-
vention for women at risk of FBC.
This study aims to identify which familial cancer services
in England recommend chemoprevention for women at high
and moderate risk of familial breast cancer in line with the
2013 NICE guidelines and if they advise primary care to pre-
scribe chemoprevention.
Methods
Ethical approval
This study was approved by the Health Research Authority
(REC reference: 19/HRA/3946) and the University of
Nottingham Faculty of Medicine and Health Sciences
Research Ethics Committee (reference: 326-1906).
Individual Research and Development offices for all potential
NHS trusts (hospital services) in England were sent local in-
formation packs and contacted to confirm capacity and
capability.
Identification of familial breast cancer services
Using the NHS directory website, all NHS trusts in England
were identified and screened for FBC services (NHS 2019b).
Information about the types of services offered was listed on
the NHS directory website and the individual trust websites;
those that did not indicate or have documentation of offering
FBC services were excluded at this initial screening stage.
Regional genetics centers were identified from the British
Society for Genetic Medicine (BSGM 2019) website.
Following this, initial contact (e-mail or telephone) was
made with all relevant departments to further clarify whether
FBC services were offered, who the lead clinicians were, and
their correct contact details. This was initiated by using the
generic contact details that were available publicly. When this
was not available, attempts for contacts were made via hospi-
tal contact numbers (NHS 2019b).
Recruitment
Once provision of FBC services and methods to contact the
lead clinician was ascertained, information about the research
and a link to the online survey were sent via e-mail. In some
cases, the secretary or staff would forward this to the lead
clinician on behalf of the researcher. Reminders were sent
after four weeks.
Questionnaire
A short questionnaire was designed to obtain the following
information:
– Does the service recommend chemoprevention for people
at high or moderate risk of FBC? If so, in which year have
they started prescribing and recommending the prescrib-
ing to primary care?
– Is chemoprevention recommended for a specific age
group?
– What chemoprevention medication is recommended?
– Which primary care organizations (called clinical
commissioning groups (CCGs)) do the hospital service
receive referrals from?
– Is there a local shared care protocol with primary care
organization for FBC chemoprevention?
– Characteristics of the service (population size, number of
consultations)
– Job role of the survey respondent
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Please see Supplementary Material 1 for the questionnaire.
The CCGs listed in the questionnaire were up to date as of
April 2019 (NHS 2019a; NHS England 2019).
The face validity of the questionnaire was checked with a
FBC specialist, a general practitioner, and a health service
researcher. The questionnaire was hosted online using the
Online Survey and a link was sent to lead clinicians of partic-
ipating trusts (Online Surveys 2019). One month after the
questionnaire was launched, minor changes to the questions’
wording was made based on feedback from participants to
align with the wording of the NICE guideline recommenda-
tions; specifically the word “recommended” was rephrased to
“offered” for high FBC risk and to “considered” for moderate
FBC risk.
The questionnaire responses were anonymized. In in-
stances of ambiguity, further clarification of responses was
sought if participants had agreed for further contact and pro-
vided contact details in the questionnaire.
Results
Response rate
Figure 1 outlines the recruitment process. Two hundred and sev-
enteen NHS trusts (hospital services) were identified from the
NHS directory as of May 2019, of which 109 trusts were iden-
tified as potential sites that provide FBC services based on
Fig. 1 Flowchart of the
recruitment for the questionnaire
study
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information from the NHS directory websites. Together with the
19 regional genetics services listed on the BSGMwebsite, initial
contact was made to a total of 128 services. Thirteen services
declined or reported having no FBC services; the reasons are
listed in Fig. 1.
Overall, the questionnaire was sent to 115 services in July–
September 2019; 53 responses were received from 51 ser-
vices. Responses from 50 services (43%) were included for
analysis: two FBC services provided two responses each, and
these were combined so that each service is represented by
one response; one response was excluded from the analysis as
it did not state which NHS trust the response was for.
Characteristics of respondents
Table 1 shows the characteristics of the 52 respondents
representing 50 services. Eighty-one percent were from breast/
breast cancer specialty. There were slightly more responses from
doctors (n = 29) than from nurses (n = 21), with 19 doctors
identifying themselves as consultants. For the two NHS trusts
that had two respondents each, both were breast specialists; in
one trust, replies were received from a nurse and a surgeon, while
the other trust was from a nurse and a physician.
The 64 services that did not respond had similar character-
istics to responders: 14% (9/64) of non-responders were ge-
netic services, with remaining sent to breast services.
Considering the health professionals sent the survey, 52%
(31/60) of non-responders were doctors, 40% (24/60) were
nurses, and 8% (5/60) were other professionals.
Characteristics of services
There was a good geographical spread of responses, as
indicated by primary care organizations (CCGs) covered
by respective familial breast cancer services (Table 1;
Fig. 2). Thirty-nine services reported the size of the pop-
ulation they served; this ranged from 14,000 to 5,500,000,
with a median of 700,000 and interquartile range of
307,500 to 2,400,000. Three services reported also receiv-
ing out of area referral and therefore could not quantify
the population size they served.
Forty-four services reported the number of consultations con-
ducted annually for familial breast cancer risk assessment; this
ranged from 50 to 3000, with a median of 237 and interquartile
range of 150 to 525. Two FBC services reported that the risk
assessments were conducted by affiliated genetic services. Four
services reported that low-risk patients were not seen in clinic.
Chemoprevention recommendation by specialist
Overall, 42 of the 50 NHS hospital services provided che-
moprevention for women at high and/or moderate risk of
FBC. Using verified information from individual primary
care organization (CCG) websites or through NHS
England websites, the 42 services were affiliated to 45
CCGs, covering a total population of 15,840,484.
Looking in more detail, 80% (40/50) of services offered
chemoprevention for high FBC risk, while 63% (31/49) of
services considered chemoprevention for moderate FBC
risk (Table 2). The map in Fig. 2 demonstrates the wide
variation in chemoprevention recommendations, even be-
tween adjacent primary care organizations.
When the responses were grouped by the respondent’s
specialty, the proportion of respondent who would recom-
mend chemoprevention was higher for genetic specialists
than for breast specialists. Although a high proportion
(78%, 31/40) of breast specialists would offer chemopre-
vention for high FBC risk, this dropped to 59% (23/39)
for moderate FBC risk. In comparison, the drop was mar-
ginal for genetic specialists from 90 (9/10, high FBC risk)
to 80% (8/10, moderate FBC risk).
Table 1 Characteristics of the 52 respondents for the 50 services
included in the analysis
Characteristics Number (%)
Specialty, n = 52
Breast 42 (81)
Genetics 10 (19)
Respondents’ health care role, n = 52
Doctor 29 (56)
Physician 20 (38)
Surgeon 9 (17)
Nurse 21 (40)
Others* 2 (4)
Regions of the CCG covered by the service**
East Midlands 4
Eastern 8
Greater Manchester 4
Kent Surrey Sussex 5
North East and North Cumbria 3
North Thames 4
North West Coast 5
North West London 2
South London 1
South West Peninsula 3
West of England 3
Wessex 3
West Midlands 3
Yorkshire and Humber 7
*Others include clinical manager and radiographer
**Total number adds up to 55 as 6 services covered 2 CCG regions and 1
service did not report its CCG regions
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When the responses were grouped by the respondent’s
health care role, there was a higher proportion of doctors
(90%, 26/29) that would recommend chemoprevention com-
pared to nurses (68%, 13/19) for high FBC risk, but the pro-
portion was similar between doctors (69%, 20/29) and nurses
(61%, 11/18) for moderate FBC risk. The related formal sta-
tistical comparison is provided in Supplementary Material 2.
Fifty-eight percent (29/50) of services recommended
chemoprevention for both high and moderate FBC risk;
22% (11/50) recommended chemoprevention for high
FBC risk but not moderate risk. For the two responses
where chemoprevention was recommended for moderate
FBC risk but not high FBC risk, both were nurses from
breast services. It was not possible to contact respondents
to clarify responses. For the seven services that did not
recommend chemoprevention for both high and moderate
FBC risk, three respondents were doctors, three were
nurses, and one was a radiographer; six were breast spe-
cialists and one was a genetic specialist.
All services that did recommend chemoprevention indicat-
ed use of tamoxifen. Fewer services discussed the use of
anastrozole or raloxifene (Table 3).
Chemoprevention for specific age groups
Most services recommended chemoprevention for women
aged 35 and over. Generally, if services recommended che-
moprevention for both high- and moderate-risk women, they
report the same age group for high and moderate risk. Two
services reported they would ensure that women of child-
bearing age had completed their family before chemopreven-
tion was recommended (Table 3).
Initiation of chemoprevention in each hospital service
i. High risk
Seventeen (43%) of the services offering chemoprevention for
high-risk women started prescribing chemoprevention before or
within three years of NICE recommending chemoprevention
(2013). Eight (20%) took more than three years to adopt the
guidelines.
The remaining 15 services discussed chemoprevention for
high-risk women but did not prescribe the medication them-
selves, with six services reporting other colleagues prescribed
the chemoprevention (in five services, the other colleagues
were General Practitioners). Of the nine genetic specialists
that would offer chemoprevention, two (22%) indicated the
genetic service prescribed chemoprevention, compared to
74% (23/31) of breast specialists.
From the free-text comments, one service commented that che-
moprevention was offered as a bridge until risk reduction surgery
for high-risk patients; two services commented that high-risk pa-
tients were more likely to choose risk reduction surgery (Table 4).
ii. Moderate risk
Fifteen (48%) of the services considering chemoprevention
for moderate-risk women started prescribing chemopreven-
tion before or within three years of NICE recommending che-
moprevention (2013). Seven (23%) services took more than
three years to adopt the guidelines.
The remaining eight services discussed chemoprevention
for moderate-risk women but did not prescribe the medication
themselves, with three services reporting other colleagues pre-
scribed the chemoprevention (Table 4). Of the eight genetic
specialists that would consider chemoprevention, three (38%)
indicated the genetic service prescribed chemoprevention,
compared to 87% (20/23) of breast specialists.
Chemoprevention recommended for high and moderate risk FBC risk 
Chemoprevention recommended for high FBC risk only
Chemoprevention recommended for moderate risk FBC only
Chemoprevention not recommended for high and moderate FBC risk
NB. One NHS trusts may receive referral from more than one clinical commisioning 
group (CCG); one CCG may refer patients to more than one NHS trusts. Information 
presented here has been simplified to the recommendations of the main NHS hospital 
trust providing FBC services to the CCG. For the purpose of this map, CCG and 
affiliated providers were verified through each individual CCG website or through NHS 
England website.
Fig. 2 Map of reported specialist recommendation for chemoprevention
across English primary care organizations (clinical commissioning
groups)
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Prescribing of chemoprevention in primary care
As indicated in Table 4, before or within three years of
NICE recommending chemoprevention, around half of ser-
vices that recommended chemoprevention indicated that
primary care should prescribe this medication. When spe-
cifically considering high-risk women, specialist services
were more likely to recommended that primary care pre-
scribe chemoprevention than initiate the medication
themselves.
The recommendation for primary care to prescribe and
specialist prescribing was similar for moderate risk (within
three years 17 vs 15 services, any time 26 vs 23 services).
Five services did not make the recommendation to primary
care for high FBC risks with reasons listed in Table 4.
Shared care protocol with primary care
Only three services reported having a shared care protocol for
prescribing chemoprevention with the local primary care
Table 2 Chemoprevention
recommendation by specialist for
women at high ormoderate risk of
familial breast cancer (FBC)
Recommendation of chemoprevention by participating services, n
(%)
Yes No
By FBC risk
High risk, n = 50 40 (80) 10 (20)
Moderate, n = 49 31 (63) 18 (37)
Combination of responses, n = 50 N (%)
Yes for high and moderate risk 29 (58)
Yes for high risk, no for moderate risk 11 (22)
No for high risk, yes for moderate risk 2 (4)
No for high and moderate risk 7 (14)
No for high, no entry for moderate risk 1 (2)
High risk, n = 50
Responses by specialty
Breast 31 (78) 9 (23)
Genetics 9 (90) 1 (10)
Responses by health care role
Doctor 26 (90) 3 (10)
Physician 18 (90) 2 (10)
Surgeon 8 (89) 1 (11)
Nurse 13 (68) 6 (32)
Others* 1 (50) 1 (50)
Moderate risk, n = 49
Responses by specialty
Breast 23 (59) 16 (41)
Genetics 8 (80) 2 (20)
Responses by health care role
Doctor 20 (69) 9 (31)
Physician 14 (70) 6 (30)
Surgeon 6 (67) 3 (33)
Nurse 11 (61) 7 (39)
Others* 0 2 (100)
*Others include clinical manager and radiographer
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organization (CCG). A third of the respondents were not sure
if there was a shared care protocol (Table 4).
Discussion
Main findings
The majority of hospital services recommended chemopre-
vention medication for women at high familial risk of breast
cancer, with smaller proportions recommending chemopre-
vention for moderate-risk women. Of these, around half
started prescribing and/or recommending primary care clini-
cians to prescribe chemoprevention within three years of the
introduction of NICE guideline, in 2013. Furthermore, it was
more likely that primary care would be recommended to pre-
scribe than specialist services start the medication themselves.
Relationship to current literature
The higher proportion of high-risk patients recommended che-
moprevention is consistent with strength of evidence for ben-
efits of chemoprevention (Fisher et al. 2005; NICE 2013a). As
well as concern about the evidence base, reluctance to pre-
scribe chemoprevention may be related to concerns of the
side-effect profile (including thromboembolism and endome-
trial cancer) and that chemoprevention was not originally li-
censed for primary prevention of breast cancer in the UK
(Cuzick et al. 2013; NICE 2013b; Smith et al. 2017).
Currently, only tamoxifen is licensed for primary prevention
of breast cancer in women at moderate to high risk in the UK
and this was only recently licensed in 2018 (MHRA 2018).
A recent qualitative study of general practitioners and fa-
milial breast cancer specialists identified the barriers of
implementing chemoprevention for FBC prevention in the
UK (Smith et al. 2016b). Some of the reasons quoted include
lack of perceived benefit and being poorly informed of the
chemoprevention. Furthermore, a focus group of family can-
cer clinicians in Australia recognized similar barriers (Keogh
et al. 2009).
Smith et al. (2016b) also identified the lack of clarity in the
NICE guideline as to who should be initiating the prescription
and offer subsequent patient care. The lack of clarity on the
most appropriate physician for prevention advice was also one
of the top five reasons for reluctance to prescribe tamoxifen or
raloxifene for FBC prevention reported in a survey of
European breast cancer specialists in 2018 (Noonan et al.
2018). The limited free-text comments from this study also
showed that the role of initiating and continuing chemopre-
vention prescribing varied according to local arrangements.
Even if chemoprevention was offered by clinicians, the
uptake among women at increased risk of breast cancer was
low (16%) (Smith et al. 2016a). This highlights the impor-
tance of efforts to ensure that chemoprevention is being rec-
ommended and clinicians and women are supported to make
the decision that is right for the individual woman.
Table 3 Chemoprevention medication for familial breast cancer risk
Familial breast cancer chemoprevention medication Number of services that offer/consider the medication for chemoprevention
High risk, n = 40 Moderate risk, n = 31
Tamoxifen 37 30
Anastrozole 23 19
Raloxifene 21 20
No entry 3 1
Is chemoprevention offered to specific age group Number of services
High risk, n = 40 Moderate risk, n = 31
Yes 27 19
No 11 10
Not sure – 1
No entry 2 1
Which age group (years) High risk, n = 27 Moderate risk, n = 19
> 30 – 1
≥ 35 16 10
> 40 1 2
> 45 1 –
40–50 1 2
40–60 1 1
Ensure completed family if child-bearing age 2 2
No valid entry 5 1
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A few services commented that high-risk patients prefer risk-
reducing surgery over chemoprevention. This is similar to pre-
vious literature where high-risk women are more likely to
choose prophylactic surgery (Evans et al. 2001). Observational
studies have shown that prophylactic surgery reduced the risk of
breast cancer by 90% and breast cancer deaths by 81–94%
(Hartmann et al. 1999). In contrast, randomized controlled trial
reported that tamoxifen reduced breast cancer risk by 35% and
there is a lack of evidence on its effect onmortality (Cuzick et al.
2007; Fisher et al. 2005; NICE 2013a).
Table 4 Years when services started prescribing/recommending chemoprevention to primary care and when shared care protocols were written
Number of services
Year when services started prescribing chemoprevention
High risk, n = 40
Before 2013 2
2013 4
1–3 years after the 2013 NICE guideline 11
> 3 years after the 2013 NICE guideline 8
Responding service offers/discusses but does not prescribe* 15
General practitioner prescribes 5
Oncologist prescribes 1
Secondary care prescribes 1
Do not prescribe/not applicable 9
Moderate risk, n = 31
Before 2013 2
2013 5
1–3 years after the 2013 NICE guideline 8
> 3 years after the 2013 NICE guideline 7
Year not specified 1
Responding service considers/discusses but does not prescribe* 8
General practitioner prescribes 2
Oncologist prescribes 1
Secondary care prescribes 1
Do not prescribe/not applicable 5
Year when services started recommending chemoprevention to primary care
High risk, n = 40
Before 2013 1
2013 7
1–3 years after the 2013 NICE guideline 14
> 3 years after the 2013 NICE guideline 9
Do not know 3
Recommends to secondary care 1
No direct recommendation but expect primary care to continue prescribing 1
Chemoprevention medication not prescribed in primary care 1
Prescribes but does not recommend to primary care 1
Decision by general practitioners 1
Management by breast team 1
Moderate risk, n = 31
Before 2013 1
2013 7
1–3 years after the 2013 NICE guideline 9
> 3 years after the 2013 NICE guideline 8
Year not specified 1
Management by local breast teams 1
Recommends to secondary care 1
Chemoprevention medication not prescribed in primary care 1
Expects that GP will continue 1
Missing 1
Written shared care protocol for prescribing chemoprevention in primary care with the local CCG, N = 50
Yes 3
No 30
Not sure 17
*Total number in the table and in the main text may not add up as more than one options provided
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Strength
To our knowledge, this is the first study to ascertain the adop-
tion of chemoprevention by specialist in England since the
introduction of the NICE guidelines. A comprehensive re-
cruitment strategy was employed nationally to get a sample
as representative as possible. The respondents comprised of a
range of health care professionals and specialty and covered a
wide geographical area.
Limitation
Although there was a low response rate and risk of responder
bias limiting the generalizability of the results, the findings are
still useful as it highlights room for improvement in
implementing the NICE guideline. Formal comparative anal-
ysis between subgroups of specialists was difficult to interpret
due to small sample size. Furthermore, it was difficult to iden-
tify the lead/senior clinician for each service and those that
responded may be completing the survey on behalf of lead/
senior clinicians. As a result, respondents may not be able to
answer comprehensively the survey questions related to clin-
ical management (such as shared care protocol with primary
care).
Identifying the hospital service provision for each primary
care organization was challenging as general practices within
these organizations may refer to different hospital services. To
reduce complexity of the presentation, the information extract-
ed in Fig. 2 was reduced to the most comprehensive service
offered for each primary care organization.
Care pathways and clinical implications
The study demonstrates majority of hospital services have
recommended chemoprevention medication for most eligible
women aged over 35, in most cases initiating the medication
themselves. As well as providing information on
implementing chemoprevention recommendations, the survey
has given a picture about the workload and configuration of
the familial cancer service across England. A few services
indicated a triage process in referral pathway with initial can-
cer risk assessment prior to clinic attendance, for example,
using a self-reported family history questionnaire. The multi-
disciplinary nature of this assessment is demonstrated in this
survey by the breadth of respondents.
In the management pathway, it appears that most women
were initially seen by breast specialist. Among services that
would recommend chemoprevention to at-risk women, a larg-
er proportion of breast specialists prescribed chemoprevention
than genetic specialists. This may reflect the longer term man-
agement of women at risk of FBC is through the breast spe-
cialist team, while the clinical genetics team takes on more of
an advisory role with no prescribing responsibilities.
Although the survey was completed by several health profes-
sionals, the doctors appeared to have lead roles in deciding on
chemoprevention. It also appears that most of the hospital
initiated prescribing of chemoprevention and delegated the
continuation to primary care but very few respondents men-
tioned formal shared care prescribing protocols between spe-
cialist and primary care.
Smith et al. have suggested this could comprise a pro forma
issued by specialists when asking general practitioners to pre-
scribe chemoprevention (Smith et al. 2016b). Similarly,
Rainey et al. reported that British women indicated a need
for protocols to standardize interaction between primary care
and hospital specialists to avoid variation in care (Rainey et al.
2020).
Of similar concern, there is question as to whether there is
variation in clinical practice across the country. To help ad-
dress the gap in implementing the NICE FBC chemopreven-
tion recommendations, guideline implementation tools, such
as those produced by NICE, may be refined and adopted.
Future research and policy recommendations
The study highlights a need for clearer shared care protocol
between specialist and primary care for the prescribing of
chemoprevention. This would improve accountability for
and compliance with chemoprevention prescribing.
One challenge of evaluating FBC services was the lack of
information on how the FBC services are configured nation-
ally. Referral pathway also differed across the country. This
may be addressed by a study that maps out the FBC service
pathways in England, for instance who conducts the risk as-
sessments, who discuss chemoprevention with patients, and
who does the actual prescribing and monitoring of chemopre-
vention. This could be facilitated by a centralized record of all
FBC services with details of key clinicians in each service.
The breast cancer charities may have a role to collate this
information.
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